VIR biotech catalysts & pipeline

VIR BIOTECHNOLOGY INC · Data as of 2026-10-25

Upcoming catalysts

VIR-5818 — Interim data

H2 2026

The Company expects to report updated dose-escalation data from its Phase 1 trial evaluating VIR-5818, a HER2-targeted PRO-XTEN ® dual-masked TCE, as a monotherapy and in combination with pembrolizumab, in the second half of 2026.

Source filing

elebsiran and tobevibart — Topline data

Q4 2026

Topline data from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026.

Source filing

elebsiran and tobevibart — Topline data

Q4 2026

Topline data from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026.

Source filing

elebsiran and tobevibart — Topline data

Q1 2027

Topline data from the ECLIPSE 2 and ECLIPSE 3 trials are expected in the first quarter of 2027.

Source filing

elebsiran and tobevibart — Topline data

Q1 2027

Topline data from the ECLIPSE 2 and ECLIPSE 3 trials are expected in the first quarter of 2027.

Source filing

elebsiran and tobevibart — Conference presentation

Nov 5–Nov 9

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of elebsiran and tobevibart for chronic hepatitis delta at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026 in Denver, CO, November 5-9, 2026.

Source filing

Explore the free biotech catalyst calendar